Abstract: An optical film for a display device, includes: a first refractive layer having an upper surface and a lower surface including first projections and second projections extending away from the lower surface in a first direction, the second projections having different heights than the first projections, the first projections having lateral sides with different angles of inclination that decrease in the first direction; and a second refractive layer disposed directly on the upper surface of the first refractive layer, the second refractive layer having a refractive index different from that of the first refractive layer.

Abstract: A hybrid catalyst composition containing a heterogeneous transition metal compound, a catalyst for olefin polymerization containing the heterogeneous transition metal compound, and a method for preparing an olefin-based polymer in which generation of a gel is suppressed using the catalyst are disclosed. The method for preparing an olefin-based polymer can provide an olefin-based polymer in which non-uniformity of the olefin-based polymer, and in particular, generation of a gel is suppressed.

Abstract: Designs of thermo-hygrostat devices capable of uniformly maintain temperature and humidity inside a chamber are disclosed. One example of such a device can include, among others, a chamber in which a sample is accommodated and internal temperature and humidity can be controlled; a lower duct provided on a first side of the chamber and sending a fluid inside the chamber to an outside of the chamber; a temperature and humidity control portion provided on the lower duct and controlling temperature and humidity of a fluid received from the lower duct.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.